REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore
REGENXBIO Inc shares were little changed in Monday morning trading, down about 0.6% at $6.97 at 10:47 a.m. EDT, as the small-cap gene-therapy developer moved without a new company-specific catalyst. The stock traded between $6.85 and $7.15, with a market value of about $365 million. Regular trading was under way on Nasdaq, whose U.S. market runs from 9:30 a.m. to 4 p.m. Eastern Time on standard weekdays. June 1 was not listed among Nasdaq’s 2026 market holidays.